Remepy raises $36M Series A for AI-drug platform, top 4% for Israeli health

What's the deal? RemepyDealroom has a profile for this one. Try Dealroom →, an Israeli biotech that pairs prescription medicines with personalised, AI-driven therapeutic software, has raised a $36 million Series A. O.G. Venture PartnersDealroom has a profile for this one. Try Dealroom → and M VenturesDealroom has a profile for this one. Try Dealroom →, the strategic investment arm of MerckDealroom has a profile for this one. Try Dealroom → KGaA, co-led the round.

Who else is in? Existing and new backers joined, including NFX, Vine VenturesDealroom has a profile for this one. Try Dealroom →, TechAvivDealroom has a profile for this one. Try Dealroom →, 97212 VenturesDealroom has a profile for this one. Try Dealroom →, Qumra CapitalDealroom has a profile for this one. Try Dealroom →, Fresh FundDealroom has a profile for this one. Try Dealroom →, PsyMed VenturesDealroom has a profile for this one. Try Dealroom →, Tadmor GroupDealroom has a profile for this one. Try Dealroom →, and IT-Farm CorpDealroom has a profile for this one. Try Dealroom →.

What's the endgame? Remepy builds hybrid drugs that combine medicines with software to boost efficacy. Its lead Hybridopa program, aimed at Parkinson's, showed improvements in motor and non-motor symptoms in Phase IIa trials and is now preparing for Phase III.

Why now? A new partnership with Merck is extending the approach into rare tumours. "Remepy is betting it can improve drug efficacy while helping drugmakers extend the commercial life of existing medicines," co-CEO Michal Tsur told Axios.

The signal: At $36 million, the round ranks in the top 4% of all Series A deals in Israeli health, a sign of investor appetite for platforms that blend software with drug development to squeeze more value from existing medicines.

Read more: Calcalist · PR Newswire

Image credit: Remepy